ClinicalTrials.gg
RecruitingNCT07629336Updated Oct 27, 2026

SAR447971 First-in-human Study

A Phase 1 interventional study of SAR447971 and Placebo in Hidradenitis and Healthy Volunteers, sponsored by Sanofi. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 27, 2026Primary completion movedStudy completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation.

MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants.

MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants.

Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20.

  • SAD20411 will enroll up to 54 participants
  • MAD20412 will enroll up to 48 participants
  • MAD24339 will enroll up to 20 participants

Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.

02

Conditions studied

  • Hidradenitis
  • Healthy Volunteers

Browse trials for

03

In context

Hidradenitis

34 studies on the registry are indexed under Hidradenitis; 9 are open to participants now.

This study's planned enrollment of 122 is close to the median of 121 across 28 interventional studies indexed under Hidradenitis.

Browse Hidradenitis studies →

Lead sponsor

Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For participation in SAD20411/MAD20412:

  • Male and/or female participant, between 18 and 55 years of age, inclusive at the time of signing the ICF.
  • Appearing healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).

For participation in MAD24339:

  • Age ≥18 and ≤65 years of age at the time of signing .
  • A diagnosis of HS made by a dermatologist at least 6 months prior to baseline visit.
  • HS lesions present in at least 2 distinct anatomic areas (e. g., left and right axilla; or left axilla and left inguino-crural fold), one of which must be Hurley Stage II or Hurley Stage III.
  • Total AN count of ≥4 at the baseline visit. - Draining tunnel count of ≤20 at the baseline visit.

Exclusion criteria

Exclusion Criteria:

For participation in SAD20411/MAD20412:

Any history or presence of cardiovascular, pulmonary, gastrointestinal, dermatologic, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, gynecologic (if female) or signs of acute illness. Active or chronic infection requiring systemic treatment within 4 weeks prior to baseline. Known history of or suspected current immunosuppression.

For participation in MAD24339:

  • Any active skin disease or condition other than HS (including but not limited to inflammatory skin diseases and cutaneous infections) that may interfere with assessment of HS.
  • Any active or chronic infection requiring systemic treatment (eg, antibiotics, antivirals, antifungals, antihelminthics) within 30 days prior to baseline.
  • Use of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit.
  • Treatment with systemic antibiotics for HS within 14 days prior to the baseline visit.
  • Non-biologic systemic therapies with potential therapeutic impact on HS \<28 days or five half-lives prior to baseline visit.
  • Any history of prior treatment with any systemic biologic with a potential therapeutic impact on HS.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (estimated)

Study arms

  • Experimental
    SAR447971

    Single or multiple doses by mouth as per protocol

    Drug: SAR447971

  • Placebo comparator
    Placebo

    Single or multiple doses by mouth as per protocol

    Drug: Placebo

Interventions

  • DrugSAR447971

    Pharmaceutical form: Tablet Route of administration: Oral

    Also known as: KT-485

  • DrugPlacebo

    Pharmaceutical form: Tablet Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. SAD20411: Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Day 1 to Day 15

  2. SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)

    Time frame: Day 1 to Day 15

  3. SAD20411: Incidence of clinically significant abnormalities in vital signs

    Time frame: Day 1 to Day 15

  4. SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)

    Time frame: Day 1 to Day 15

  5. MAD20412: Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Day 1 to Day 29

  6. MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)

    Time frame: Day 1 to Day 29

  7. MAD20412: Incidence of clinically significant abnormalities in vital signs

    Time frame: Day 1 to Day 29

  8. MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)

    Time frame: Day 1 to Day 29

  9. MAD24339: Incidence of treatment emergent adverse events (TEAEs)

    Time frame: Day 1 to Day 42

  10. MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)

    Time frame: Day 1 to Day 42

  11. MAD24339: Incidence of clinically significant abnormalities in vital signs

    Time frame: Day 1 to Day 42

  12. MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)

    Time frame: Day 1 to Day 42

Secondary outcomes

  1. SAD20411: PK parameter - Cmax

    Maximum serum concentration observed.

    Time frame: Day 1 to Day 15

  2. SAD20411: PK parameter - tmax

    Time to reach Cmax.

    Time frame: Day 1 to Day 15

  3. SAD20411:PK parameter - AUC

    Area under the plasma concentration versus time curve extrapolated to infinity.

    Time frame: Day 1 to Day 15

  4. SAD20411: PK parameter - Cmax in fed and fasted state

    Maximum serum concentration observed.

    Time frame: Day 1 to Day 15

  5. SAD20411: PK parameter - tmax in fed and fasted state

    Time to reach Cmax.

    Time frame: Day 1 to Day 15

  6. SAD20411: PK parameter - AUC in fed and fasted state

    Area under the plasma concentration versus time curve extrapolated to infinity.

    Time frame: Day 1 to Day 15

  7. MAD20412: PK parameter - Cmax

    Maximum serum concentration observed.

    Time frame: Day 1 to Day 22

  8. MAD20412: PK parameter - tmax

    Time to reach Cmax.

    Time frame: Day 1 to Day 22

  9. MAD20412: PK parameter - AUC0-tau

    Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval

    Time frame: Day 1 to Day 22

  10. MAD24339: IRAK4 expression in skin biopsies before and after repeated doses of SAR447971

    Time frame: Day 1 to Day 42

  11. MAD24339: Plasma SAR447971 concentrations at pre-specified visits and time points

    Time frame: Day 1 to Day 42

07

Study locations

1 of 1 sites recruiting
  • Investigational Site Number: 5280001
    Leiden, 2333, Netherlands
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Apr 2028, 22 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Feb 2028 → Apr 2028 and completion Feb 2028 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2026
First posted
Jun 5, 2026
StartActual
May 26, 2026
Primary completionEst.
Apr 17, 2028was Feb 2028
CompletionEst.
Apr 17, 2028was Feb 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 16, 2028→Apr 17, 2028
Oct 27, 2026
Study completion
Feb 16, 2028→Apr 17, 2028
Oct 27, 2026
Enrollment
114→122
Oct 27, 2026
Eligibility
1 exclusion criterion edited, 2 added
What changed in the criteria
Exclusion criteria
  • AddedUse of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit.
  • AddedTreatment with systemic antibiotics for HS within 14 days prior to the baseline visit.
  • EditedUse of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit. - Treatment with systemic antibiotics for HS within 14 days prior to the baseline visit. - Non-biologic systemic therapies with potential therapeutic impact on HS <28 days or five half-lives prior to baseline visit.
Oct 27, 2026
Primary outcomes
4 time frame changed
What changed in the outcomes
  • Time frameMAD20412: Incidence of treatment emergent adverse events (TEAEs)Day 1 to Dat 29 → Day 1 to Day 29
  • Time frameMAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Day 1 to Dat 29 → Day 1 to Day 29
  • Time frameMAD20412: Incidence of clinically significant abnormalities in vital signsDay 1 to Dat 29 → Day 1 to Day 29
  • Time frameMAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Day 1 to Dat 29 → Day 1 to Day 29
Oct 27, 2026
Secondary outcomes
3 time frame changed
What changed in the outcomes
  • Time frameMAD20412: PK parameter - CmaxDay 1 to Dat 29 → Day 1 to Day 22
  • Time frameMAD20412: PK parameter - tmaxDay 1 to Dat 29 → Day 1 to Day 22
  • Time frameMAD20412: PK parameter - AUC0-tauDay 1 to Dat 29 → Day 1 to Day 22
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Feb 16, 2028→Apr 17, 2028
    Study completion Feb 16, 2028→Apr 17, 2028
    Enrollment 114→122
    Eligibility 1 exclusion criterion edited, 2 added
    What changed in the criteria
    Exclusion criteria
    • AddedUse of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit.
    • AddedTreatment with systemic antibiotics for HS within 14 days prior to the baseline visit.
    • EditedUse of prescription topical therapies for the treatment of HS within 14 days prior to the baseline visit. - Treatment with systemic antibiotics for HS within 14 days prior to the baseline visit. - Non-biologic systemic therapies with potential therapeutic impact on HS <28 days or five half-lives prior to baseline visit.
    Primary outcomes 4 time frame changed
    What changed in the outcomes
    • Time frameMAD20412: Incidence of treatment emergent adverse events (TEAEs)Day 1 to Dat 29 → Day 1 to Day 29
    • Time frameMAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Day 1 to Dat 29 → Day 1 to Day 29
    • Time frameMAD20412: Incidence of clinically significant abnormalities in vital signsDay 1 to Dat 29 → Day 1 to Day 29
    • Time frameMAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Day 1 to Dat 29 → Day 1 to Day 29
    Secondary outcomes 3 time frame changed
    What changed in the outcomes
    • Time frameMAD20412: PK parameter - CmaxDay 1 to Dat 29 → Day 1 to Day 22
    • Time frameMAD20412: PK parameter - tmaxDay 1 to Dat 29 → Day 1 to Day 22
    • Time frameMAD20412: PK parameter - AUC0-tauDay 1 to Dat 29 → Day 1 to Day 22
    + 3 other changes: verification date, description and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07629336
Lead sponsor
Sanofi
Collaborators
Kymera Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jun 5, 2026
Start date
May 26, 2026
Primary completion
Apr 17, 2028 (estimated)
Completion
Apr 17, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion